Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Fpkm differences between versions of Cufflinks

    I have run the same paired-end SOLiD sample on both version of Cufflinks (0.9.3 and 1.0.3).

    When looking at the transcripts.gtf file from both versions, I observe that the FPKMs from the same transcript are different.

    1)Does anyone know what changed between the two versions to cause this difference?

    When I tried to run the latest version of Cuffcompare (1.0.3) on my paired-end SOLiD sample, no FPKM values were reported--they were all zero.

    2) does anyone know why this is the case and what can be done to correct this?


    Thank You!

  • #2
    Just noticed this old post, but since no-one had replied, figured why not:

    Pre-1.2.0 Cufflinks did not calculate FPKMs in a deterministic manner -- perhaps the EM was randomly initialized -- you could run the same version of Cufflinks on the same dataset 10 times and get 10 different FPKMs.

    Granted, the variance would be small, but occasionally it would not. I've calculated that about 1% of the time the FPKM confidence intervals between runs would not overlap (for the same gene).

    Anyway, this problem has been fixed as of 1.2.0.

    Ariel

    Comment

    Latest Articles

    Collapse

    • seqadmin
      Understanding Genetic Influence on Infectious Disease
      by seqadmin




      During the COVID-19 pandemic, scientists observed that while some individuals experienced severe illness when infected with SARS-CoV-2, others were barely affected. These disparities left researchers and clinicians wondering what causes the wide variations in response to viral infections and what role genetics plays.

      Jean-Laurent Casanova, M.D., Ph.D., Professor at Rockefeller University, is a leading expert in this crossover between genetics and infectious...
      09-09-2024, 10:59 AM
    • seqadmin
      Addressing Off-Target Effects in CRISPR Technologies
      by seqadmin






      The first FDA-approved CRISPR-based therapy marked the transition of therapeutic gene editing from a dream to reality1. CRISPR technologies have streamlined gene editing, and CRISPR screens have become an important approach for identifying genes involved in disease processes2. This technique introduces targeted mutations across numerous genes, enabling large-scale identification of gene functions, interactions, and pathways3. Identifying the full range...
      08-27-2024, 04:44 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by seqadmin, Today, 06:25 AM
    0 responses
    13 views
    0 likes
    Last Post seqadmin  
    Started by seqadmin, Yesterday, 01:02 PM
    0 responses
    12 views
    0 likes
    Last Post seqadmin  
    Started by seqadmin, 09-18-2024, 06:39 AM
    0 responses
    14 views
    0 likes
    Last Post seqadmin  
    Started by seqadmin, 09-11-2024, 02:44 PM
    0 responses
    14 views
    0 likes
    Last Post seqadmin  
    Working...
    X